-
1 × ₨ 95.00
-
2 × ₨ 970.00
-
1 × ₨ 400.00
-
1 × ₨ 500.00
-
1 × ₨ 105.00
-
1 × ₨ 265.00
-
1 × ₨ 545.11
-
1 × ₨ 272.30
-
1 × ₨ 720.00
-
1 × ₨ 114.00
-
1 × ₨ 66.00
-
1 × ₨ 227.92
-
1 × ₨ 63.00
-
1 × ₨ 10.00
-
1 × ₨ 680.00
-
1 × ₨ 50.50
-
1 × ₨ 120.00
-
1 × ₨ 700.00
-
1 × ₨ 80.00
-
1 × ₨ 1,155.00
-
1 × ₨ 720.00
-
2 × ₨ 336.00
-
1 × ₨ 139.87
-
1 × ₨ 200.00
-
1 × ₨ 1,440.00
-
1 × ₨ 349.00
-
1 × ₨ 745.00
-
1 × ₨ 114.00
-
1 × ₨ 1,180.00
-
1 × ₨ 560.00
-
1 × ₨ 252.00
-
2 × ₨ 645.00
-
1 × ₨ 140.00
-
1 × ₨ 430.00
-
1 × ₨ 104.00
-
1 × ₨ 104.00
-
1 × ₨ 392.83
-
1 × ₨ 94.02
-
1 × ₨ 15.24
-
1 × ₨ 107.00
-
1 × ₨ 648.00
-
1 × ₨ 90.00
-
1 × ₨ 191.58
-
1 × ₨ 885.00
-
1 × ₨ 655.00
-
1 × ₨ 200.00
-
1 × ₨ 22.32
-
1 × ₨ 287.37
-
1 × ₨ 520.00
Roll over image to zoom in
SITAPIN 50MG
₨ 277.00₨ 308.00 (-10%)
- For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
- Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
Reviews
There are no reviews yet.